Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 10, 2010, Pages 1844-1859

  Noris, Marina ^a   Caprioli, Jessica ^a   Bresin, Elena ^a   Mossali, Chiara ^a   Pianetti, Gaia ^a   Gamba, Sara ^a   Daina, Erica ^a   Fenili, Chiara ^a   Castelletti, Federica ^a   Sorosina, Annalisa ^a   Piras, Rossella ^a   Donadelli, Roberta ^a   Maranta, Ramona ^a   Van Der Meer, Irene ^a,b   Conway, Edward M ^c   Zipfel, Peter F ^d   Goodship, Timothy H ^e   Remuzzi, Giuseppe ^a,f  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d HANS KNÖLL INSTITUTE   (Germany)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; MEMBRANE COFACTOR PROTEIN; THROMBOMODULIN;

ADULT; ARTICLE; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FAMILIAL ATYPICAL HEMOLYTIC UREMIC SYNDROME; FEMALE; GENE MUTATION; GENETIC COMPLEMENTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONSET AGE; PHENOTYPE; PROGNOSIS; REMISSION; SPORADIC ATYPICAL HEMOLYTIC UREMIC SYNDROME; STEROID THERAPY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED, 80 AND OVER; ANTIGENS, CD46; AUTOANTIBODIES; CHI-SQUARE DISTRIBUTION; COMPLEMENT C3; COMPLEMENT FACTOR H; COMPLEMENT SYSTEM PROTEINS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MUTATION; PEDIGREE; PHENOTYPE; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; THROMBOMODULIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77958587405     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02210310     Document Type: Article

References (48)

1. Ruggenenti P, Noris M, Remuzzi G: Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60: 831-846, 2001 (Pubitemid 34205784)
2. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB: A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 70: 423-431, 2006 (Pubitemid 44141568)
3. Scheiring J, Andreoli SP, Zimmerhackl LB: Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 23: 1749-1760, 2008
4. Noris M, Remuzzi G: Atypical hemolytic-uremic syndrome. N Engl J Med 361: 1676-1687, 2009
5. Kavanagh D, Goodship TH: Update on evaluating complement in hemolytic uremic syndrome. Curr Opin Nephrol Hypertens 16: 565-571, 2007 (Pubitemid 350293750)
6. Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Cnaan A, Trachtman H: Non-enteropathic hemolytic uremic syndrome: Causes and short-term course. Am J Kidney Dis 43: 976-982, 2004
7. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, Lopez-Trascasa M, Sanchez-Corral P, Morgan BP, Rodriguez de Cordoba S: Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 104: 240-245, 2007
8. Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP: Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112: 4948-4952, 2008
9. Roumenina LT, Jablonski M, Hue C, Blouin J, Dimitrov JD, Dragon-Durey MA, Cayla M, Fridman WH, Macher MA, Ribes D, Moulonguet L, Rostaing L, Satchell SC, Mathieson PW, Sautes-Fridman C, Loirat C, Regnier CH, Halbwachs-Mecarelli L, Fremeaux-Bacchi V: Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 114: 2837-2845, 2009
10. Delvaeye M, Noris M, DeVriese A, Esmon C, Esmon N, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway E: Mutations in thrombomodulin in hemolytic-uremic syndrome. N Engl J Med 361: 345-357, 2009
11. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Fremeaux-Bacchi V: Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16: 555-563, 2005
12. Jozsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C: Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111: 1512-1514, 2008
13. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ: Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4 and with mutations in CFH, CFI, CD46, and C3 in patients with atypical haemolytic uraemic syndrome. Blood 115: 379-387, 2009
14. Abarrategui-Garrido C, Martinez-Barricarte R, Lopez-Trascasa M, de Cordoba SR, Sanchez-Corral P: Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 114: 4261-4271, 2009
15. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G: Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108: 1267-1279, 2006
16. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C: Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18: 2392-2400, 2007
17. Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C, Sautes-Fridman C, Villoutreix BO, Blom AM, Fremeaux-Bacchi V: Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kidney Int 77: 339-349, 2010
18. Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, Fakhouri F, Provost F, Fridman WH, Thervet E, Legendre C, Zuber J, Fremeaux-Bacchi V: Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 8: 1694-1701, 2008
19. Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Hughes A, Wood KM, Goodship JA, Goodship TH: Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 3: e431, 2006
20. Skerka C, Jozsi M, Zipfel PF, Dragon-Durey MA, Fremeaux-Bacchi V: Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost 101: 227-232, 2009
21. Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M: Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 12: 3385-3395, 2003
22. Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinaglio P, Bucchioni S, Sonzogni A, Bonanomi E, Sonzogni V, Platt JL, Perico N, Noris M: Hemolytic uremic syndrome: A fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant 5: 1146-1150, 2005
23. Saland JM, Ruggenenti P, Remuzzi G: Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 20: 940-949, 2009
24. Remuzzi G, Ruggenenti P, Codazzi D, Noris M, Caprioli J, Locatelli G, Gridelli B: Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 359: 1671-1672, 2002
25. Dragon-Durey MA, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C, Fridman WH, Fremeaux-Bacchi V: The high frequency of complement factor H-related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 46: 447-450, 2009
26. Lhotta K, Janecke AR, Scheiring J, Petzlberger B, Giner T, Fally V, Wurzner R, Zimmerhackl LB, Mayer G, Fremeaux-Bacchi V: A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol 4: 1356-1362, 2009
27. Loirat C, Noris M, Fremeaux-Bacchi V: Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 23: 1957-1972, 2008
28. Girardi G, Bulla R, Salmon JE, Tedesco F: The complement system in the pathophysiology of pregnancy. Mol Immunol 43: 68-77, 2006
29. Damman J, Schuurs TA, Ploeg RJ, Seelen MA: Complement and renal transplantation: From donor to recipient. Transplantation 85: 923-927, 2008
30. Licht C, Fremeaux-Bacchi V: Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thromb Haemost 101: 271-278, 2009
31. Jha V, Murthy MS, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V: Secondary membranoproliferative glomerulonephritis due to hemolytic uremic syndrome: An unusual presentation. Ren Fail 20: 845-850, 1998
32. Jozsi M, Heinen S, Hartmann A, Ostrowicz CW, Halbich S, Richter H, Kunert A, Licht C, Saunders RE, Perkins SJ, Zipfel PF, Skerka C: Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol 17: 170-177, 2006
33. Seifert PS, Hansson GK: Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 9: 802-811, 1989
34. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB: Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24: 687-696, 2009
35. Davin JC, Buter N, Groothoff J, van Wijk J, Bouts A, Strain L, Goodship T: Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr Nephrol 24: 1757-1760, 2009
36. Davin JC, Strain L, Goodship TH: Plasma therapy in atypical haemolytic uremic syndrome: Lessons from a family with a factor H mutation. Pediatr Nephrol 23: 1517-1521, 2008
37. Pangburn MK, Rawal N, Cortes C, Alam MN, Ferreira VP, Atkinson MA: Polyanion-induced self-association of complement factor H. J Immunol 182: 1061-1068, 2009
38. Bresin E, Daina E, Noris M, Castelleti F, Stefanov R, Hill P, Goodship TM, Remuzzi G: HUS/TTP ftIRoRaF: Outcome of renal transplantation in patients with non-Shiga toxin-associated haemolytic uremic syndrome: Prognostic significance of genetic background. Clin J Am Soc Nephrol 1: 88-99, 2006
39. Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH: Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 6: 1948-1952, 2006
40. Saland JM, Shneider BL, Bromberg JS, Shi PA, Ward SC, Magid MS, Benchimol C, Seikaly MG, Emre SH, Bresin E, Remuzzi G: Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4: 201-206, 2009
41. Sharfuddin AA, Sandoval RM, Berg DT, McDougal GE, Campos SB, Phillips CL, Jones BE, Gupta A, Grinnell BW, Molitoris BA: Soluble thrombomodulin protects ischemic kidneys. J Am Soc Nephrol 20: 524-534, 2009
42. Olie KH, Goodship TH, Verlaak R, Florquin S, Groothoff JW, Strain L, Weening JJ, Davin JC: Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: Successful treatment with intensive plasma exchanges and ganciclovir. Am J Kidney Dis 45: e12-e15, 2005
43. Hirt-Minkowski P, Schaub S, Mayr M, Schifferli JA, Dickenmann M, Fremeaux-Bacchi V, Steiger J: Haemolytic uraemic syndrome caused by factor H mutation: Is single kidney transplantation under intensive plasmatherapy an option? Nephrol Dial Transplant 24: 3548-3551, 2009
44. Nurnberger J, Witzke O, Saez AO, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M: Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360: 542-544, 2009
45. Gruppo RA, Rother RP: Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 360: 544-546, 2009
46. Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E: Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 4: 1312-1316, 2009
47. Chatelet V, Fremeaux-Bacchi V, Lobbedez T, Ficheux M, de Ligny BH: Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 9: 2644-2645, 2009
48. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T: Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 55: 708-711, 2010